Preoperative immunotherapy in oncology
For some types of tumor, neoadjuvant ICI therapy is standard and/or about to be approved. Special care must be taken in managing ICI toxicity. In view of the adverse effects and cost of ICI, it will be important to identify biomarkers for a higher likelihood of benefit.
Authors
- Sylvie Lorenzen
- Servet Bölükbas (ORCID: https://orcid.org/0000-0001-8275-5957)
- Ralf‐Dieter Hofheinz (ORCID: https://orcid.org/0000-0001-5972-8504)
- Stefan Fichtner‐Feigl (ORCID: https://orcid.org/0000-0002-6710-562X)
- Sibylle Loibl (ORCID: https://orcid.org/0000-0001-6488-4958)
- M. Sebastian (ORCID: https://orcid.org/0000-0003-3724-1353)
Publication Details
- Journal
- Deutsches Ärzteblatt international
- Published
- 2026-01-16
- DOI
- https://doi.org/10.3238/arztebl.m2025.0209
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00